A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/14/2006	US7135497 Spinal administration of at least one beta 2 adrenergic agonist such as clenbuterol and salbutamol; neurodegenerative diseases; improved locomotor function and neuromuscular strength
11/14/2006	US7135496 Antitumor, anticancer agents; rheumatic diseases; autoimmune diseases
11/14/2006	US7135495 Indole derivatives
11/14/2006	US7135494 Antitumoral carbazoles
11/14/2006	US7135493 HDAC inhibitor
11/14/2006	US7135492 Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion
11/14/2006	US7135491 5-Aryltetrazole compounds and uses thereof
11/14/2006	US7135490 Method for the treatment of glomerulonephritis
11/14/2006	US7135489 Cyclooxygenase inhibitors; antiinflammatory agents
11/14/2006	US7135488 Pyrrolyl-thiazole derivatives
11/14/2006	US7135487 Sulphonamide derivatives
11/14/2006	US7135486 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
11/14/2006	US7135485 Pioglitazone hydrochloride
11/14/2006	US7135484 Azabicyclic compounds are central nervous system active agents
11/14/2006	US7135483 Substituted heterocyclic compounds for treating multidrug resistance
11/14/2006	US7135482 Aids therapy; viricides
11/14/2006	US7135481 Naphthalimide compositions and uses thereof
11/14/2006	US7135480 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis
11/14/2006	US7135479 Compounds which are both serotonin reuptake inhibitors and antagonists of the 5HT1A receptor
11/14/2006	US7135478 Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them
11/14/2006	US7135477 Administering N-(2-[N',N'-diethylamino]-5-[N''-(4-fluorophenylsulfonyl)-N''-propargylamino]pyrimidin-4-yl)-4'-(pyrrolidin-1-ylcarbonyloxy)-L-phenylalanine as an antiinflammatory agent treating rheumatoid arthritis
11/14/2006	US7135476 Corticotropin releasing factor antagonists; anxiolytic agents; (2,3,5',6',-Tetrahydro)-2'-methyl-4'-(N-propyl-N-cylopropylmethyl-amino) spiro[(1H)indene-1,8'-(7H)quinazoline]; (2,3,5',6',-Tetrahydro)-2'-methyl-4'-(N-propyl-N-cylopropylmethyl-amino) spiro[(1H)indene-1,7'-(5H)cyclopentapyrimidine]
11/14/2006	US7135475 Antidiabetic agents
11/14/2006	US7135474 In combination with organic nitrate or nitric oxide donors or inhibitors of cyclic GMP metabolism; erectile dysfunction or female sexual dysfunction
11/14/2006	US7135473 Cyclic diamine compound with condensed-ring groups
11/14/2006	US7135472 3-Heterocyclic benzylamide derivatives as potassium channel openers
11/14/2006	US7135471 Aryl oximes
11/14/2006	US7135470 Thienopyridazines as IKK inhibitors
11/14/2006	US7135469 Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
11/14/2006	US7135468 Antibacterial compounds
11/14/2006	US7135467 HIV integrase inhibitors
11/14/2006	US7135466 used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy.
11/14/2006	US7135465 Sustained release beadlets containing stavudine
11/14/2006	US7135464 Method of administering decitabine
11/14/2006	US7135462 Hepatitis C virus inhibitors
11/14/2006	US7135287 Producing a human antibody display library; providing a mouse transgenic genome expressing human immunoglobulins to produce a plurality of human antibodies
11/14/2006	US7135286 Pharmaceutical and diagnostic business systems and methods
11/14/2006	US7135197 Mixtures of group V compounds such as bismuth subsalicylate, water and antideposit agents having storage stability, used for prohylaxis of nausea, dyspepsia or diarrhea
11/14/2006	US7135196 Iron compositions
11/14/2006	US7135193 Liposome compositions of porphyrin photosensitizers
11/14/2006	US7135192 Lipid, Dna complex with detectable labels
11/14/2006	US7135189 Compositions and techniques for localized therapy
11/14/2006	US7135177 Immunoliposomes that optimize internalization into target cells
11/14/2006	US7135162 Agent for diagnosing and treating malignant tumors
11/14/2006	CA2417887C Particulate composition of eletriptan
11/14/2006	CA2408191C Biocidal polymers based on guanidine salts
11/14/2006	CA2379572C Polymorphic salt
11/14/2006	CA2362233C Process for cross-linking hyaluronic acid to polymers
11/14/2006	CA2343099C Role of human kis (hkis) as an inhibitory kinase of the cyclin-dependentkinase inhibitor p27. compositions, methods and uses thereof to control cell proliferation
11/14/2006	CA2342271C Gem substituted hydroxamic acids
11/14/2006	CA2319849C Use of inorganic-organic complexes in a compound
11/14/2006	CA2314623C Use of at least one hydroxystilbene as an anti-glycation agent
11/14/2006	CA2308873C Use of at least one inhibitor of at least one calcium channel in wrinkle treatment
11/14/2006	CA2296427C 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivatives
11/14/2006	CA2294783C Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
11/14/2006	CA2274669C 1,5-benzodiazepine derivatives
11/14/2006	CA2267376C Process for producing depsipeptide derivatives and novel intermediates therefor
11/14/2006	CA2263846C Novel pyranoside derivatives
11/14/2006	CA2261787C Multi-layered osmotic device
11/14/2006	CA2244363C Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
11/14/2006	CA2228049C Two-phase preparation
11/14/2006	CA2214072C Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
11/14/2006	CA2210674C New topical compounds containing very small amounts of melatonin or its derivatives and their use in cosmetics
11/14/2006	CA2171836C Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
11/14/2006	CA2156432C New derivatives of glutamic and aspartic acids, a method of preparing them, and their use as drugs for enhancing memory and learning
11/14/2006	CA2128955C Tricyclic benzazepine vasopressin antagonists
11/14/2006	CA2128493C Aminobenzoic acid derivatives
11/14/2006	CA2111386C Substituted benzoylguanidines, process for their preparation, their use as pharmaceutical or diagnostic, and pharmaceutical containing them
11/14/2006	CA2100812C Substituted aminothienopyridines, a process for their preparation and their use as medicaments
11/13/2006	CA2790058A1 Herceptin® adjuvant therapy
11/13/2006	CA2540547A1 Herceptin adjuvant therapy
11/12/2006	CA2546392A1 Phenylpyridinylpiperazine derivatives, a process for their preparation and pharmaceutical compositions containing them
11/12/2006	CA2546387A1 Phenyl-pyridinyl-piperazine derivatives, process for the preparation thereof and pharmaceutical compositions containing said derivatives
11/09/2006	WO2006119507A2 Non-nucleotide composition and method for inhibiting platelet aggregation
11/09/2006	WO2006119504A2 Fused heterocyclic compounds, and compositions and uses thereof
11/09/2006	WO2006119499A2 Use of phycotoxins in veterinary applications
11/09/2006	WO2006119498A2 Pharmaceutical compositions with synchronized solubilizer release
11/09/2006	WO2006119451A1 Pyrimidines and pyrazines useful as modulators of ion channels
11/09/2006	WO2006119390A1 Pyridines useful as modulators of ion channels
11/09/2006	WO2006119389A2 Quinine-containing controlled-release formulations
11/09/2006	WO2006119384A1 Spirocyclic bicyclolides
11/09/2006	WO2006119353A2 Dopamine receptor agonists in the treatment and prevention of hiv-induced dementia
11/09/2006	WO2006119346A2 Ketocarotenoids from adonis palaestina
11/09/2006	WO2006119329A2 Compositions and methods for the treatment of neurodegenerative diseases
11/09/2006	WO2006119313A2 6-11 bridged oxime erythromycin derivatives
11/09/2006	WO2006119309A2 19,26,27-TRINOR-1α,25-DIHYDROXYVITAMIN D3 COMPOUNDS
11/09/2006	WO2006119295A2 Compositions and methods for the treatment of neurodegenerative diseases
11/09/2006	WO2006119284A2 Conjugated aromatic compounds for diagnosis and therapy
11/09/2006	WO2006119260A2 Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity
11/09/2006	WO2006119211A2 Methods and compositions for treating ocular disorders
11/09/2006	WO2006119154A1 Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis
11/09/2006	WO2006119130A2 Drug delivery coating for use with a medical device and methods of treating vascular injury
11/09/2006	WO2006119083A2 Treating gastrointestinal diseases with modulation of retonic acid
11/09/2006	WO2006119071A2 Methods and uses of leukotriene b4 hydroxylases to treat diseases
11/09/2006	WO2006119032A1 Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor
11/09/2006	WO2006119018A2 Drug delivery coating for use with a medical device and methods of treating vascular injury
11/09/2006	WO2006118953A2 Method of treating multiple myeloma using 17-aag of 17-ag of a prodrug of either
11/09/2006	WO2006118948A2 Therapeutic compositions
11/09/2006	WO2006118941A1 Methods of supressing uv light-induced skin carcinogenesis
11/09/2006	WO2006118897A1 Acid and base salt forms of gaboxadol

1 ... 4011 4012 4013 4014 4015 4016 4017 4018 4019 4020 4021 4022 4023 4024 4025 4026 4027 4028 4029 4030 4031 ... 7860